CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia derived from plasmacytoid dendritic cells (pDCs). It is associated with a remarkably poor prognosis and unmet need for better therapies. Recently, the first-in-class CD123-targeting therapy, tagraxofusp, was appro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Elodie Bôle-Richard, Naveen Pemmaraju, Blandine Caël, Etienne Daguindau, Andrew A. Lane
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-05-01
Colecção:Cancers
Assuntos:
BPDCN
leukemia
AML
CD123
tagraxofusp
bispecific antibody
Acesso em linha:https://www.mdpi.com/2072-6694/14/9/2287
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados